Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 938-716-9 | CAS number: -
Endpoint summary
Administrative data
Description of key information
GSK2619294A is expected to have adverse effects upon the adrenals, immune system and bone.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
· In view of the relatively potent glucocorticoid activity of GSK2619294A, this substance is expected to possess typical target organ toxicity of that class of compound if absorbed.
· Past occupational overexposure to corticosteroids has resulted in systemic corticosteroid activity, including Cushing’s syndrome and adrenal suppression. Consequences of exposure also include delayed wound healing and susceptibility to infection and reduced responses to stress. This is more likely to be the consequence of repeated overexposure over a period of time.
Therapeutic use of glucocorticoids for long periods and at higher doses has been associated with an increased incidence of osteoporosis and avascular necrosis of bone.Justification for classification or non-classification
As the test material has demonstrated activity equivalent to known potent glucocorticoids and based on these known effects (as discussed above), the material has been assigned the classification of Reproductive toxicity; Category 1B.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
